vs
Side-by-side financial comparison of Five9, Inc. (FIVN) and Bio-Techne (TECH). Click either name above to swap in a different company.
Five9, Inc. is the larger business by last-quarter revenue ($300.3M vs $295.9M, roughly 1.0× Bio-Techne). On growth, Five9, Inc. posted the faster year-over-year revenue change (7.8% vs -6.4%). Over the past eight quarters, Five9, Inc.'s revenue compounded faster (10.3% CAGR vs 4.2%).
Five9, Inc. is a leading global provider of cloud-native contact center software and solutions. It serves enterprises of all sizes across retail, healthcare, financial services, and technology sectors, offering omnichannel customer engagement tools, AI-powered automation, workforce management, and analytics to boost customer experience and operational efficiency.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
FIVN vs TECH — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $300.3M | $295.9M |
| Net Profit | — | $38.0M |
| Gross Margin | 55.4% | 64.6% |
| Operating Margin | 6.6% | 18.4% |
| Net Margin | — | 12.8% |
| Revenue YoY | 7.8% | -6.4% |
| Net Profit YoY | — | 68.3% |
| EPS (diluted) | $0.22 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $300.3M | $295.9M | ||
| Q3 25 | $285.8M | — | ||
| Q2 25 | $283.3M | $317.0M | ||
| Q1 25 | $279.7M | $316.2M | ||
| Q4 24 | $278.7M | $297.0M | ||
| Q3 24 | $264.2M | $289.5M | ||
| Q2 24 | $252.1M | $306.1M | ||
| Q1 24 | $247.0M | $303.4M |
| Q4 25 | — | $38.0M | ||
| Q3 25 | $18.0M | — | ||
| Q2 25 | $1.2M | $-17.7M | ||
| Q1 25 | $576.0K | $22.6M | ||
| Q4 24 | — | $34.9M | ||
| Q3 24 | $-4.5M | $33.6M | ||
| Q2 24 | $-12.8M | $40.6M | ||
| Q1 24 | $-7.1M | $49.1M |
| Q4 25 | 55.4% | 64.6% | ||
| Q3 25 | 55.0% | — | ||
| Q2 25 | 54.9% | 62.7% | ||
| Q1 25 | 55.0% | 67.9% | ||
| Q4 24 | 56.0% | 65.3% | ||
| Q3 24 | 53.8% | 63.2% | ||
| Q2 24 | 53.0% | 66.4% | ||
| Q1 24 | 53.6% | 67.4% |
| Q4 25 | 6.6% | 18.4% | ||
| Q3 25 | 5.6% | — | ||
| Q2 25 | -0.6% | -7.5% | ||
| Q1 25 | -1.9% | 12.2% | ||
| Q4 24 | 1.5% | 16.0% | ||
| Q3 24 | -5.8% | 13.8% | ||
| Q2 24 | -7.7% | 15.0% | ||
| Q1 24 | -8.4% | 22.1% |
| Q4 25 | — | 12.8% | ||
| Q3 25 | 6.3% | — | ||
| Q2 25 | 0.4% | -5.6% | ||
| Q1 25 | 0.2% | 7.1% | ||
| Q4 24 | — | 11.7% | ||
| Q3 24 | -1.7% | 11.6% | ||
| Q2 24 | -5.1% | 13.3% | ||
| Q1 24 | -2.9% | 16.2% |
| Q4 25 | $0.22 | $0.24 | ||
| Q3 25 | $0.21 | — | ||
| Q2 25 | $0.01 | $-0.11 | ||
| Q1 25 | $0.01 | $0.14 | ||
| Q4 24 | $0.16 | $0.22 | ||
| Q3 24 | $-0.06 | $0.21 | ||
| Q2 24 | $-0.17 | $0.26 | ||
| Q1 24 | $-0.10 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $232.1M | $172.9M |
| Total DebtLower is stronger | — | $260.0M |
| Stockholders' EquityBook value | $785.8M | $2.0B |
| Total Assets | $1.8B | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $232.1M | $172.9M | ||
| Q3 25 | $193.4M | — | ||
| Q2 25 | $205.5M | $162.2M | ||
| Q1 25 | $370.3M | $140.7M | ||
| Q4 24 | $362.5M | $177.5M | ||
| Q3 24 | $291.0M | $187.5M | ||
| Q2 24 | $175.7M | $152.9M | ||
| Q1 24 | $240.2M | $145.3M |
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M | ||
| Q1 24 | — | $389.0M |
| Q4 25 | $785.8M | $2.0B | ||
| Q3 25 | $775.3M | — | ||
| Q2 25 | $717.4M | $1.9B | ||
| Q1 25 | $664.3M | $2.0B | ||
| Q4 24 | $622.2M | $2.1B | ||
| Q3 24 | $565.6M | $2.1B | ||
| Q2 24 | $525.9M | $2.1B | ||
| Q1 24 | $483.6M | $2.0B |
| Q4 25 | $1.8B | $2.5B | ||
| Q3 25 | $1.8B | — | ||
| Q2 25 | $1.7B | $2.6B | ||
| Q1 25 | $2.1B | $2.6B | ||
| Q4 24 | $2.1B | $2.7B | ||
| Q3 24 | $2.0B | $2.7B | ||
| Q2 24 | $1.9B | $2.7B | ||
| Q1 24 | $1.9B | $2.7B |
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× | ||
| Q1 24 | — | 0.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $83.6M | — |
| Free Cash FlowOCF − Capex | $77.3M | — |
| FCF MarginFCF / Revenue | 25.8% | — |
| Capex IntensityCapex / Revenue | 2.1% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $201.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $83.6M | — | ||
| Q3 25 | $59.2M | — | ||
| Q2 25 | $35.1M | $98.2M | ||
| Q1 25 | $48.4M | $41.1M | ||
| Q4 24 | $49.8M | $84.3M | ||
| Q3 24 | $41.1M | $63.9M | ||
| Q2 24 | $19.9M | $75.5M | ||
| Q1 24 | $32.4M | $81.0M |
| Q4 25 | $77.3M | — | ||
| Q3 25 | $48.7M | — | ||
| Q2 25 | $31.6M | $93.3M | ||
| Q1 25 | $43.7M | $31.0M | ||
| Q4 24 | $40.5M | $77.5M | ||
| Q3 24 | $26.7M | $54.7M | ||
| Q2 24 | $13.1M | $57.5M | ||
| Q1 24 | $20.4M | $64.5M |
| Q4 25 | 25.8% | — | ||
| Q3 25 | 17.0% | — | ||
| Q2 25 | 11.1% | 29.4% | ||
| Q1 25 | 15.6% | 9.8% | ||
| Q4 24 | 14.5% | 26.1% | ||
| Q3 24 | 10.1% | 18.9% | ||
| Q2 24 | 5.2% | 18.8% | ||
| Q1 24 | 8.3% | 21.3% |
| Q4 25 | 2.1% | — | ||
| Q3 25 | 3.7% | — | ||
| Q2 25 | 1.2% | 1.5% | ||
| Q1 25 | 1.7% | 3.2% | ||
| Q4 24 | 3.3% | 2.3% | ||
| Q3 24 | 5.4% | 3.2% | ||
| Q2 24 | 2.7% | 5.9% | ||
| Q1 24 | 4.8% | 5.4% |
| Q4 25 | — | — | ||
| Q3 25 | 3.29× | — | ||
| Q2 25 | 30.38× | — | ||
| Q1 25 | 84.00× | 1.82× | ||
| Q4 24 | — | 2.42× | ||
| Q3 24 | — | 1.90× | ||
| Q2 24 | — | 1.86× | ||
| Q1 24 | — | 1.65× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FIVN
Segment breakdown not available.
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
